Xtant Medical Holdings (XMS) AI Stock Analysis

Xtant Medical Holdings

(Frankfurt:XMS)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Solid Gross MarginsDespite volatile revenue and earnings, gross margin remained roughly in the low-60% range across 2025 and TTM. This indicates the product portfolio retains favorable underlying economics, providing a foundation for future operating leverage if biologics growth and procedural volumes recover.

Negative Factors

Revenue ContractionThe sharp quarterly decline and lower annual guidance show that recent commercial momentum has not yet offset asset sales, license-revenue cessation, and biologics weakness. Prolonged top-line pressure would reduce operating leverage and make recovery in earnings and cash generation less certain.

Xtant Medical Holdings (XMS) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 39.31M
Dividend Yield: ―
Average Volume (3M): 7,833
Price to Earnings (P/E): -3.4
Beta (1Y): 0.54
Revenue Growth: -20.06%
EPS Growth: -111.15%
Country: Germany
Employees: 151
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Xtant Medical Holdings Business Overview & Revenue Model

Company Description

Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological sur...

Xtant Medical Holdings Earnings Call Summary

Earnings Call Date:Aug 10, 2026(Q2-2026)|% Change Since:-31.89%|Next Earnings Date:May 14, 2019

Earnings Call SentimentNegative

The call presents meaningful strategic and commercial progress — notably the Dilon distribution agreement, integration of 17 new sales reps, product launches (Trivium Shaped) and expanded TAM — which position Xtant for future growth. However, the quarter showed significant near-term financial deterioration: sharp year-over-year revenue decline, gross margin compression, a swing to a net loss and negative adjusted EBITDA, reduced cash balances and a modestly reduced full-year revenue guide. Many negative results are tied to one-time transitions (asset sales, license cessation, Dilon integration) and strategic investments, but the immediate financial metrics are weak while visibility into near-term cash/earnings recovery remains uncertain.

Positive Updates

Strategic Dilon Distribution Agreement and Sales Team Integration

Acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST Bellows and hired Dilon's U.S. team of 17 salespeople and 2 regional managers integrated into Xtant's commercial organization; this expands sales coverage and materials-management relationships and is positioned to drive cross-selling of Xtant's biologics portfolio.

Negative Updates

Significant Revenue Decline

Total revenue of $23.0M in Q2 2026 versus $35.4M in Q2 2025 (a decline of ~35%) and versus a pro forma Q2 2025 of $24.8M (a decline of ~7.3%); management cited asset sales to Companion Spine and cessation of certain license reimbursements as drivers.

Company Guidance

Xtant modestly lowered full‑year 2026 revenue guidance to $99 million–$103 million (from $101 million–$105 million previously), citing lower‑than‑expected biologics revenue in Q2 and persistent headwinds in its amnio line through the back half of the year; Q2 revenue was $23.0 million (vs. $35.4M GAAP / $24.8M pro forma in Q2 2025), gross margin was 57.9% (vs. 68.6% LY) and adjusted EBITDA was a loss of $2.7 million (vs. +$6.9M LY). Management stressed it still expects accelerating sequential biologics growth in H2 as the newly integrated Dilon team (17 reps + 2 regional managers) and an expanded field organization (now >25 reps and multiple national accounts) are fully deployed; HEMOBLAST contributed ~$1.5 million in Q2 (primarily recognized net—approximately $600k–$700k of additional revenue would have been recognized if shipped under Xtant POs), and the company continues to model HEMOBLAST transactional volume at over $1 million per month on a gross basis once transitions complete.

Xtant Medical Holdings Risk Analysis

Xtant Medical Holdings disclosed 55 risk factors in its most recent earnings report. Xtant Medical Holdings reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.In April 2026, we entered into a Distribution Agreement with Dilon Technologies, Inc. and hired sales personnel in connection therewith, which will result in increased sales and marketing costs and involves other risks, which could adversely affect our business, operating results, and financial condition.Q2, 2026

Xtant Medical Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:XMS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	71Outperform	$1.12B	16.59	28.39%	―	3.14%	―
SYK	71Outperform	$111.95B	30.88	15.61%	1.21%	7.87%	22.82%
ZBH	69Neutral	$18.03B	22.89	6.36%	1.02%	8.62%	0.09%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OFIX	50Neutral	$369.44M	-5.91	-14.05%	―	2.99%	51.77%
IART	44Neutral	$991.96M	75.98	1.24%	―	0.84%	―

* Healthcare Sector Average

Performance Comparison

DE:XMS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:XMS	Xtant Medical Holdings Inc	0.25	-0.46	-64.76%
IART	Integra Lifesciences	12.75	1.45	12.83%
OFIX	Orthofix Medical Inc.	9.07	-5.80	-39.00%
SYK	Stryker Corp	291.86	-66.78	-18.62%
ZBH	Zimmer Biomet Holdings	94.52	-7.57	-7.41%
BVS	Bioventus, Inc.	13.32	5.77	76.49%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Xtant Medical Holdings AI Stock Analysis